NanoString Rounds Out Commercial Management Team with New Vice Presidents of Sales, Marketing

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced it has rounded out its commercial management team with the hiring of Chris Grimley as Vice President of Marketing and Katherine Webster as Vice President of Worldwide Sales. Mr. Grimley and Ms. Webster will report to the company’s recently appointed Chief Commercial Officer, Barney Saunders, Ph.D.

Mr. Grimley and Ms. Webster bring more than 40 collective years of commercial sales, marketing and product development experience at market-leading life science technology companies. Mr. Grimley will be responsible for driving global demand for the company's nCounter® Analysis System and assay portfolio and will help identify opportunities to continue to expand the applications for the system. As Vice President of Worldwide Sales, Ms. Webster will be responsible for advancing NanoString’s global academic, commercial and governmental customer relationships and driving worldwide sales. Both executives will play a key role in preparing the company for worldwide sales and marketing of high-value clinical diagnostics products based on the nCounter System, pending appropriate regulatory approvals.

Mr. Grimley joins NanoString from Agilent Technologies where he was most recently Senior Director, Genomics Marketing leading strategic and product marketing programs across microarrays, target enrichment products for next-generation sequencing, qPCR systems, bioreagents and software solutions. His prior experience includes 14 years at Applied Biosystems (now Life Technologies) where he held a number of senior product management positions, including directing the real-time PCR and microarray system product lines. He began his career as a research associate at Genentech. Mr. Grimley holds a Bachelor of Science degree in Biochemistry from San Francisco State University.

Ms. Webster joins NanoString from Qiagen where she was Senior Sales Director for the Life Science business directing revenue growth activities across North America. Prior executive management positions include Vice President of Sales for the 454 Sequencing Center at 454 Life Sciences (now a Roche Company) and President, Biotage Biosystems Division Worldwide. Her past experience also includes senior management positions at Molecular Staging, Celera Genomics, Chemdex and PE Applied Biosystems (now Life Technologies). Ms. Webster holds a Bachelor of Science degree in Chemistry from the State University of New York, Syracuse.

“The past year has been marked with rapid growth of the new applications launched on our multiplexed digital counting platform and a series of strategic, high-caliber executive hires,” said Dr. Saunders. “We are delighted to welcome these established industry professionals to help take NanoString to the next level of commercial success.”

More information is available at

About NanoString Technologies, Inc.

NanoString Technologies is a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.


NanoString Technologies, Inc.
Nicole Litchfield, 415-793-6468
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Genetics  Infectious Diseases  Medical Devices  Oncology  Pharmaceutical  Research  Science